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Introduction: CD40 ligand (CD40L) blockade has demonstrated efficacy in experimental autoimmune models.
However, clinical trials of hu5c8, an anti-human CD40L IgG1 antibody, in systemic lupus erythematosus (SLE) were
halted due to an increased incidence of thrombotic events. This study evaluated CDP7657, a high affinity PEGylated
monovalent Fab' anti-CD40L antibody fragment, to assess whether an Fc-deficient molecule retains efficacy while
avoiding the increased risk of thrombotic events observed with hu5c8.
Methods: The potency and cross-reactivity of CDP7657 was assessed in in vitro assays employing human and
non-human primate leukocytes, and the capacity of different antibody formats to activate platelets in vitro was
assessed using aggregometry and dense granule release assays. Given the important role CD40L plays in regulating
humoral immunity, in vivo efficacy was assessed by investigating the capacity of Cynomolgus monkeys to generate
immune responses to the tetanus toxoid antigen while the potential to induce thrombotic events in vivo was
evaluated after repeat dosing of antibodies to Rhesus monkeys. A PEGylated anti-mouse CD40L was generated to
assess efficacy in the New Zealand Black/White (NZB/W) mouse model of SLE.
Results: CDP7657 dose-dependently inhibited antigen-specific immune responses to tetanus toxoid in Cynomolgus
monkeys, and in contrast to hu5c8, there was no evidence of pulmonary thrombovasculopathy in Rhesus monkeys.
Aglycosyl hu5c8, which lacks Fc receptor binding function, also failed to induce thrombotic events in Rhesus
monkeys. In vitro experiments confirmed that antibody constructs lacking an Fc, including CDP7657, did not induce
human or monkey platelet activation. A PEGylated monovalent Fab' anti-mouse CD40L antibody also inhibited
disease activity in the NZB/W mouse model of SLE after administration using a therapeutic dosing regimen where
mice received antibodies only after they had displayed severe proteinuria.
Conclusions: These findings demonstrate for the first time that anti-CD40L antibodies lacking a functional Fc
region do not induce thrombotic events in Rhesus monkeys and fail to activate platelets in vitro but, nevertheless
retain pharmacological activity and support the investigation of CDP7657 as a potential therapy for systemic lupus
erythematosus and other autoimmune diseases.* Correspondence: Tony.Shock@ucb.com; linda.burkly@biogenidec.com
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CD40 ligand (CD40L), or CD154, is expressed on acti-
vated T lymphocytes, and through interactions with its re-
ceptor CD40, plays a pivotal role in regulating the
interplay between T cells and other cell types [1–3]. The
CD40L/CD40 pair is known to mediate cognate T cell help
for B cells, resulting in increased B cell proliferation and
differentiation, antibody production and isotype class
switching. CD40L also promotes the formation of germi-
nal centers in lymph nodes and B-cell survival. CD40L
therefore holds significant promise as a therapeutic target
in autoimmune disease, and blockade of CD40L has been
shown to be highly efficacious in several inflammatory and
autoimmune model systems [4–8].
CD40L has also been detected on other immune
and non-lymphoid cells [3] and is present in platelets
[9, 10]. Within seconds of being stimulated by plate-
let agonists, CD40L is presented on the surface of
platelets, and is subsequently shed as soluble CD40L
(sCD40L) [9]. Furthermore, a role for platelet-derived
CD40L in regulating adaptive immunity and throm-
bosis has been suggested [11–14].
Hu5c8, a monoclonal IgG1 antibody against CD40L,
was evaluated in clinical trials for a range of auto-
immune diseases. Results from a phase 2 study in pa-
tients with systemic lupus erythematosus (SLE) were
encouraging, with significant reductions in disease bio-
markers, including circulating levels of autoantibodies
and marked increases in C3 levels [15–17]. However,
despite this promising evidence of clinical effect, further
development of hu5c8 was discontinued because of an
increased incidence of treatment-emergent cardiovascu-
lar thrombotic events (TEs) [18]. More recently, in a
study of hu5c8 in the Rhesus monkey, numerous TEs in-
cluding pulmonary vascular thrombi and vasculopathy
were found after administration of hu5c8 [19], suggest-
ing that the Rhesus monkey is a relevant and sensitive
pre-clinical model for induction of TEs by anti-CD40L
IgG1 antibodies in humans. The mechanism by which
hu5c8 induces TEs in humans remains unclear. In vitro
analyses have shown that immune complexes (IC) con-
sisting of sCD40L and an anti-CD40L monoclonal anti-
body can trigger platelet aggregation [12, 20]. This effect
seems to be dependent on the anti-CD40L monoclonal
antibody carrying a functional Fc region, and signaling
through the FcγRIIa (CD32a) Fc receptor on the platelet
surface [12, 20, 21].
To evaluate whether one could achieve the therapeutic
potential of CD40L blockade while removing the TE risk
hypothesized to be due to platelet activation, this paper
describes the generation and testing of an anti-CD40L
antibody fragment lacking a functional Fc region. To in-
crease the circulating half-life of this monovalent Fab'
antibody fragment, a 40 kDa polyethylene glycol (PEG)moiety was conjugated via a chemical linker, and this
new molecule was designated CDP7657. CDP7657 is
currently undergoing phase 1 clinical trials in patients
with SLE.
A series of experimental studies was conducted utiliz-
ing a variety of antibody constructs, including CDP7657
and aglycosyl IgG forms of anti-CD40L antibodies, in
order to determine the importance of Fc function and
valency for the efficacy and safety of anti-CD40L anti-
bodies. Here, we describe findings demonstrating that
CDP7657 inhibits antigen-specific immune responses to
the tetanus toxoid (TT) antigen in Cynomolgus mon-
keys. The profound efficacy of an anti-mouse CD40L
monovalent PEGylated Fab' fragment was also demon-
strated in a murine model of SLE. In addition, the Fc re-
gion of anti-CD40L antibodies was shown to be
important for the activation of platelets in vitro and for
the induction of TEs in Rhesus monkeys in vivo.
Methods
Antibodies and reagents
Anti-CD40L antibodies used were: hu5c8, a humanized
anti-human CD40L intact IgG1 monoclonal antibody
(Biogen Idec, Cambridge, MA, USA); aglycosyl hu5c8, a
mutant form of hu5c8 with reduced FcR binding (Biogen
Idec, MA, USA); CDP7657, a monovalent Fab' PEGylated
anti-CD40L antibody (UCB Pharma, Slough, UK); M90, a
mouse anti-human CD40L intact IgG1 monoclonal anti-
body (hybridoma from ATCC, Manassas, VA, USA); MR1
Fab' PEG, a monovalent, murinized Fab' PEGylated anti-
mouse CD40L (UCB Pharma, Slough, UK). Soluble CD40L
was from Peprotech (Rocky Hill, NJ, USA), phycoerythrin
(PE)-labeled CD40-Fc fusion protein was from Ancell
(Bayport, MN, USA) and thrombin receptor agonist
peptide (TRAP) was from Sigma (St Louis, MO, USA).
Activity and cross-reactivity experiments
BIAcore (surface plasmon resonance) experiments were
performed to calculate the affinity (KD, equilibrium dis-
sociation constant) of CDP7657 for CD40L and involved
capturing the antibody using an anti-human Fab' antibody
and then titrating human sCD40L protein over the immo-
bilized antibodies. The KD for hu5c8 was assessed after
capture with an anti-Fc antibody. Potency was assessed in
two flow cytometry-based, cell-based assays: the binding
of a PE-labeled CD40–Fc fusion protein to CD40L-
expressing D1.1 Jurkat cells and an assay of T-cell-
dependent B cell activation, involving overnight co-culture
of CD40L-expressing D1.1 cells with the Ramos B cell
line and monitoring intercellular adhesion molecule 1
(ICAM-1) expression on the latter cells. Non-human pri-
mate cross-reactivity of CDP7657 was measured in satur-
ation binding experiments using a broad-range antibody
titration on peripheral blood lymphocytes isolated from
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activated in vitro to express CD40L. Human blood sam-
ples were obtained under a licence (#12504) granted to
UCB under Section 16 (2) (e) (ii) of the Human Tissue
Act (UK) and all donors provided their written consent to
participate.
Immune response to TT in a Cynomolgus monkey model
Groups of six Cynomolgus monkeys (n = 3/sex) were ad-
ministered a single intravenous (i.v.) dose of antibody or
saline and, after 4 h or 48 h, an intramuscular (i.m.) dose
of TT (0.5 mL), except in the dose–response study,
where 20 mg/kg IgG antibodies and 40 mg/kg PEGylated
antibodies were used. Plasma was isolated at various
time intervals for anti-TT analyses by ELISA. Plates were
coated with TT, incubated with plasma samples and after
washing, binding was detected using horseradish perox-
idase (HRP)-conjugated anti-monkey IgG antibodies.
Mean anti-TT IgG titer ± standard deviation were calcu-
lated and where appropriate, one-way analysis of vari-
ance (ANOVA) was performed. As parametric statistical
methods were used, the data should be declared to have
been found normally distributed and of equal variance.
NZB/W SLE nephritis mouse model
All experiments were conducted under protocols ap-
proved by the Animal Welfare and Ethical Review Body
of UCB (UK) in accordance with the Animals (Scientific
Procedures) Act 1986. Female NZB/NZW F1 mice
(Harlan, UK) aged 18 weeks, were housed in cages of
seven or eight mice, in a temperature- and humidity-
controlled room, with 12-h light–dark cycles. All ani-
mals received food and water ad libitum.
Female NZB/NZW F1 mice were assessed for disease
progression from 18 weeks of age with levels of protein
(mg/dL) in the urine measured by Albustix (Bayer,
Leverkusen, Germany) twice a week. After recording a
proteinuria level ≥300 mg/dL on one occasion, mice were
randomized into one of two dosing groups and dosed sub-
cutaneously (s.c.) with either saline or 100 mg/kg MR1
Fab' PEG. Animals entered disease remission when a pro-
teinuria level ≤100 mg/dL was measured on two conse-
cutive occasions, and disease relapse was classified as
animals that scored ≥300 mg/dL on two consecutive
occasions. Remission and relapse data were subjected
to the Mann–Whitney U test to compare MR1 Fab'
PEG to saline control. Survival data were analyzed by
the log-rank test.
Platelet activation by anti-CD40L antibodies
Platelet aggregometry
The protocol for obtaining human blood for all platelet
studies was approved by the Florida Hospital Institu-
tional Review Board and donors provided their writtenconsent to participate. Washed platelet aggregation stud-
ies were performed as described previously [22]. Briefly,
washed platelets (four human donors, two Rhesus mon-
keys) were suspended in HEPES buffer, and platelets
were adjusted to 250/nL and analyzed by light transmis-
sion aggregometry (300 μL/assay). Baseline traces were
established and preformed anti-CD40L ICs were added
to a final concentration of 200 nM. For studies with pre-
formed IC, antibody formats (hu5c8, aglycosyl hu5c8 or
CDP7657) were combined with sCD40L in a ratio of one
antibody to one antigen homotrimer, the molar stoichio-
metric equivalent of this being one antibody per three
sCD40L antigen monomers. Aggregations were moni-
tored for at least 6 minutes.
Measurement of platelet dense granule release
The serotonin release assay was performed as described
previously [21]. Briefly, platelets in platelet-rich plasma
(one human donor, four Rhesus monkeys) were labeled
with 14C-radiolabeled serotonin (0.1 μCi/mL), incubated
for 45 minutes at 37 °C, washed in apyrase buffer (to
prevent spurious activation), then re-suspended in
albumin-free Tyrode’s assay buffer. Antibody solutions
were clarified by centrifugation (16,100 rpm, 15 minutes)
before adding to assay wells to a final concentration of
500 nM. For studies with preformed IC, antibody for-
mats (hu5c8, aglycosyl hu5c8 or CDP7657) were com-
bined with sCD40L in a ratio of one antibody to one
antigen homotrimer, the molar stoichiometric equivalent
of this being one antibody per three sCD40L antigen
monomers. ICs, pre-incubated for 5–20 minutes prior to
assay, were then added to microtiter plate wells to
achieve a final concentration of 500 nM.
Assessment of TE in Rhesus monkeys
Studies in Cynomolgus and Rhesus monkeys were con-
ducted at Charles River Laboratories (NV, USA),
followed international Good Laboratory Practice (GLP)
standards and were conducted in accordance with the
regulations of the USDA Animal Welfare Act (2010) and
in compliance with the testing facility’s Animal Welfare
Assurance (A4112-01) filed with the National Institutes
of Health (NIH); the protocols were approved by the
Charles River Laboratories Institutional Animal Care &
Use Committee.
A head-to-head comparative 8-week study investigated
the occurrence of TEs with the monovalent Fab' PEG
CDP7657 and two intact monoclonal antibodies, hu5c8
and aglycosyl hu5c8. These agents were administered i.v.
at 50 mg/kg/week for 8 weeks to Rhesus monkeys (n =
4/sex/group) and compared with saline-injected controls
(n = 2/sex).
A 3-month GLP pivotal safety study assessed potential
dose-dependent TE occurrence with CDP7567 and general
Table 2 CDP7657 cross-reactivity with human and non-human
primate (Cynomolgus and Rhesus monkey) CD40L
Cell type KD (nM)
Human Cynomolgus monkey Rhesus monkey
Donor 1 Donor 2 Donor 1 Donor 2 Donor 1 Donor 2
PBMC 1.57 1.41 1.50 1.13 1.21 0.80
PBMC peripheral blood mononuclear cell
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or 200 mg/kg/week i.v. (n = 5/sex/group) for 12 weeks.
Control animals (n = 10/sex) received saline. At the end of
the treatment period, additional satellite groups (n = 1 − 4/
sex/group) were used to assess any reversibility effects over
4 and 6 months. For both studies, monoclonal antibodies
were administered by bolus i.v. injection over approxi-
mately 60 s. Standard toxicology endpoints were moni-
tored. At necropsy, lungs were insufflated with neutral-
buffered formalin and allowed to fully fix by immersion in
additional neutral-buffered formalin.
Macroscopic examination of pulmonary tissues included
partial dissection of pulmonary and bronchial arteries. A
total of 29 histopathology sections were taken from each
animal. Five histopathology sections were collected from
each of the four largest lung lobes (left and right diaphrag-
matic, and left and right apical). Three sections were pre-
pared from the three smallest lung lobes (left and right
middle lobes, and intermediate lobe).
Results
CDP7657 inhibits the humoral immune response
CDP7657 has a very high affinity for CD40L and potently
neutralizes CD40L in functional cell-based assays, measur-
ing CD40 binding to CD40L, and CD40L-dependent B cell
activation (Table 1). It had similar affinity for human and
non-human primate (Rhesus monkey and Cynomolgus
monkey) CD40L (Table 2), which was expected as the
CD40L protein sequences of Rhesus monkeys and Cyno-
molgus monkeys are identical, and share 98 % of their
identity with human CD40L. CDP7657 possesses a higher
affinity than hu5c8 and both antibodies have similar activ-
ities in cell-based assays (Table 1). CDP7657 does not bind
to rodent CD40L and, therefore, it was necessary to inves-
tigate the in vivo efficacy of CDP7657 in non-human pri-
mates. The model employed monitored the impact of
CDP7657 on the antibody response to TT in Cynomolgus
monkeys, a model previously used to evaluate hu5c8
efficacy [5].
A single-dose study was conducted to assess the efficacy
of CDP7657 at three dose levels (5, 20 and 60 mg/kg i.v.),
compared with hu5c8 at 20 mg/kg i.v., a dose shown to be
effective in previous studies with this antibody [23]. The
pharmacokinetics were considered to be typical for the
antibody constructs used, and were dose-proportional.




CD40L-dependent B-cell activation (ICAM-1 expression) (IC50)
*Activity in this assay is very sensitive to the valency of anti-CD40L antibodies teste
intercellular adhesion molecule 1and hu5c8 at the same dose of 20 mg/kg i.v (Fig. 1
legend).
The serum IgG responses elicited by TT provocation
were inhibited dose-dependently by CDP7657, and the
inhibition was statistically significant with 60 mg/kg i.v.
(P <0.05) (Fig. 1). The degree of inhibition of the IgG re-
sponse seen with CDP7657 at 60 mg/kg i.v. was similar
to that achieved with hu5c8 at 20 mg/kg i.v. A similar
pattern of inhibition was observed when the secondary
immune response was assessed after administration of a
second dose of antibody to the animals and re-challenge
with TT (see Additional file 1). A reduction in potency
was seen with an aglycosyl derivative of hu5c8 compared
to hu5c8 (Fig. 2). In this molecule, a single amino acid
change in the Fc region prevents normal N-glycosylation
of the antibody [23]. This change does not alter the af-
finity of the antibody for CD40L, but does ablate anti-
body effector function including FcγR binding. Aglycosyl
hu5c8 was shown to have a similar potency to CDP7657
in this model. Taken together, these data demonstrate
that Fc function plays a role in the potency of anti-
CD40L antibodies in this in vivo model, although
equivalent efficacy was achieved with CDP7657 when
dosed at 60 mg/kg.
A murine anti-CD40L monovalent Fab' PEG antibody
fragment inhibits disease in SLE-prone NZB/W F1 mice
To assess whether an anti-CD40L antibody construct lack-
ing an Fc region retains efficacy in experimental models of
autoimmune disease, a PEGylated monovalent Fab' anti-
mouse antibody, MR1 Fab' PEG, was generated. Female
NZB/NZW F1 mice spontaneously develop an auto-
immune disease, which has many of the pathological
features of human SLE. MR1 Fab' PEG demonstrates pro-
found inhibition in this model when dosed prophylactically
(i.e., before disease onset), but has also been assessed under
more stringent conditions using a therapeutic dosingCDP7657 Hu5c8
7.9 pM 33 pM
44 ng/mL (490 pM) 44 ng/mL (293 pM)
83 ng/mL (920 pM) 38 ng/mL (253 pM)*
d, and the IC50 for hu5c8 Fab is 977 ng/mL (n = 20). CD40L CD40 ligand, ICAM
Fig. 1 Inhibition of humoral immune response in Cynomolgus monkeys: CDP7657 dose response. CDP7657 (various doses) was compared with a
single dose of hu5c8 (20 mg/kg). Animals were administered a single dose of antibody or saline i.v. on day 1 and challenged with tetanus toxoid
(TT) 4 h later. Data are expressed as the mean anti-TT IgG titer ± standard deviation; *P <0.05 (one-way analysis of variance), compared with
control, was considered to be statistically significant. Maximum concentration (Cmax) and area under the concentration–time curve from time 0
until 19 days (AUC0–19) values were calculated for each tested dose of antibody, day 19 being the last day anti-TT response was measured after
anti-CD40 ligand administration. Cmax was 163, 704 and 2,088 μg/mL for 5, 20 and 60 mg/kg doses of CDP7657, respectively. AUC0–19 was 713,
2476 and 10,488 μg/day/mL for 5, 20 and 60 mg/kg CDP7657, respectively. Cmax and AUC0–19 for hu5c8 (20 mg/kg) were 414 and 3,186
μg/day/mL, respectively
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only after demonstrating high levels of proteinuria
(>300 mg/dL). Under these conditions, treatment with a
single dose of MR1 Fab' PEG resulted in protection from
disease, with 50 % of animals entering remission (protein-
uria level ≤100 mg/dL measured on two consecutive occa-
sions) compared to a saline control group, resulting in
increased survival of the treated animals (Fig. 3). These
data show that a monovalent PEGylated anti-CD40L anti-
body fragment profoundly affects disease remission in an
experimental model of SLE, as had previously been dem-
onstrated for full-length anti-CD40L antibodies [24].Fig. 2 Inhibition of humoral immune response in Cynomolgus monkeys: c
antibody or saline 2 days prior to administration of tetanus toxoid (TT); the
PEGylated formats (n = 6 for all groups). The IgG anti-TT titers in plasma samPlatelet activation by anti-CD40L antibodies requires
FcγRIIa interaction
As well as confirming that CDP7657 was efficacious in
both rodent and Cynomolgus monkey models, it was im-
portant to determine whether this construct mitigated the
Fc-mediated platelet activation believed to be responsible
for the prothrombotic events observed with hu5c8. Using
platelet function tests, the possible prothrombotic activity
of hu5c8, aglycosyl hu5c8 and CDP7657 was explored
using human and Rhesus monkey blood.
In washed platelets from human healthy donors, im-
mune complex (IC) consisting of hu5c8 with sCD40Lomparison of antibody formats. Animals received a single i.v. dose of
doses were 20 mg/kg for the IgG antibodies and 40 mg/kg for the
ples were assessed from days 10 to 31
Fig. 3 Disease remission and increased survival after therapeutic dosing with MR1 Fab' polyethylene glycol (PEG) in NZB/NZW mice. a Remission
and relapse of proteinuria levels in NZB/W mice after a single dose of 100 mg/kg MR1 Fab' PEG (n = 14) compared to saline control (n = 15). Data
are expressed as the percentage of animals scoring ≥300 mg/dL proteinuria, with remission classified as two consecutive scores ≤100mg/dL
proteinuria; P = 0.0146 (Mann–Whitney U test) compared with saline control. b Percentage of mice surviving in each group over time; P <0.0031
(log-rank test) compared to saline control, and was considered to be statistically significant. Tx therapy
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aglycosyl hu5c8 IC and CDP7657 IC were completely
inactive (Fig. 4a). Hu5c8, aglycosyl hu5c8 and CDP7657
were all inactive in the absence of sCD40L, as was
sCD40L alone (see Additional file 2). M90, another anti-
human CD40L antibody, also induced platelet aggrega-
tion in an intact murine IgG format, when combined
with sCD40L. Additionally, hu5c8 IC consistently in-
duced a strong serotonin dense granule release from iso-
lated platelets (Fig. 4b) but CDP7657 and aglycosyl
hu5c8 were completely inactive.
Comparable experiments performed using Rhesus mon-
key blood samples were consistent with the human find-
ings. As shown in Fig. 4c, hu5c8 IC caused complete
aggregation of washed Rhesus monkey platelets, whereas
CDP7657 IC had no aggregatory effect. Similarly, hu5c8
IC induced a strong serotonin dense granule release fromRhesus monkey platelets (Fig. 4d). Aglycosyl hu5c8 IC and
CDP7657 IC, in addition to hu5c8, aglycosyl hu5c8,
CDP7657 or sCD40L alone were completely inactive.
Overall, these data suggest that aglycosyl hu5c8 IC and
CDP7657 IC do not induce platelet aggregation in both
human and Rhesus monkey test systems; the same was
true even when Rhesus monkey platelets were primed
with sub-optimal ADP (See Additional file 3). These data
are consistent with earlier reports showing that CD40L
antibodies require Fc-mediated signaling through FcγRIIa
to activate platelets [12] and that aglycosyl hu5c8 (incap-
able of binding FcR) and antibody fragments lacking an Fc
region are without activity in these assay systems.
Lack of evidence of TEs in Rhesus monkeys with CDP7657
Given that CDP7657 did not lead to activation of platelets
from either humans or Rhesus monkeys, an evaluation to
Fig. 4 Platelet activation by anti-CD40 ligand (anti-CD40L)antibodies requires FcγRIIa interaction. a In vitro platelet aggregation isolated from
humans. Preformed immune complex (IC) (anti-CD40L antibodies plus soluble CD40 ligand (sCD40L)) was incubated with isolated platelets from
four human volunteers; representative data from one volunteer are shown. Traces show the percentage of platelet aggregation over a 6-minute
time period from one donor, but is representative of four donors. b In vitro dense granule release from human platelets. Anti-CD40L antibodies
(final concentration 500 nM, with/without sCD40L) were incubated with isolated human platelets (n = 4), and 14C-radiolabeled serotonin release
was measured. Data are plotted as mean percentage serotonin release (average of the means of four donors (SRA)). Error bars are standard
deviation for the mean percentage SRA values of the four donors. c In vitro platelet aggregation isolated from Rhesus monkeys. Preformed IC was
incubated with isolated platelets from two Rhesus monkeys (RH1 and RH2). Traces show the percentage of platelet aggregation over a
6-minute time period from one donor, but is representative of two donors. d In vitro dense granule release from Rhesus monkey platelets.
Preformed IC or antibody solutions (final concentrations 500 nM) were incubated with isolated platelets from four Rhesus monkeys (black bars) or
one healthy human donor (gray bars), and 14C-radiolabeled serotonin release was measured. Thrombin receptor agonist peptide (TRAP) (100 μM)
was included as a positive control. Data are plotted as in b.
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in vivo was undertaken. A head-to-head, 8-week i.v. study
to compare the thromboembolic potential of CDP7657
and hu5c8 was conducted in Rhesus monkeys. Hu5c8 at
50 mg/kg/week i.v. produced widespread pulmonary arter-
ial intravascular thrombosis and/or intimal hyperplasiaand associated secondary pathology changes in the lungs
(Table 3; Fig. 5a and b). By contrast, CDP7657 and other
anti-CD40L antibody constructs lacking a functional Fc
region, also administered at 50 mg/kg/week i.v., were
associated with minimal pulmonary changes that were
comparable in incidence and severity to those found in
Table 3 Thromboembolic potential of different anti-CD40L anti-

















1 (25) 1 116 0.9
(n = 2/sex)a




3 (37.5) 3 232 1.3
(n = 4/sex)
Hu5c8 5 (62.5) 41 232 17.6
(n = 4/sex)
Thrombembolic events were defined as the occurrence of thrombus, an
organizing thrombus or intimal hyperplasia. aHistoric control group of Rhesus
monkeys that had received i.v. saline for up to 6 months; bone animal died on
day 2, which was unrelated to CDP7657 treatment; cvalues in parentheses do
not include animals removed from the study for humane reasons unrelated to
the study
Fig. 5 Histopathology of Rhesus monkey lungs showed no findings attribu
sections of pulmonary arteries/arterioles from Rhesus monkeys that receive
thrombus formation is accompanied by marked, irregular thickening of the
of smooth muscle, deposition of pale basophilic fibrillar extracellular matrix
entrapped red blood cells. In c and d fibrin microthrombi adhere to the endo
microthrombi are formed and lysed continually within the venous circulatory
prevent them from obstructing the vital coronary, cerebral and renal arteries.
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two out of eight hu5c8-treated animals, there was a
treatment-related decrease in platelet count (56 % and 42 %
on day 37, compared with pre-treatment levels) but this
was not observed in any CDP7657-treated animal.
Based on the encouraging in vitro and in vivo data
generated with CDP7657, a longer study with higher
dose levels of CDP7657 was undertaken. In this study,
Rhesus monkeys were dosed weekly for 3 months with
CDP7657 at doses up to 200 mg/kg i.v. No gross or his-
topathologic findings attributable to CDP7657 were ob-
served in the lungs of treated animals, either at the end of
the 3-month treatment period or during a period of up to
6 months following the end of dosing (Table 4). Micro-
scopic thrombi (including mature organizing thrombi)
with a similar very low incidence and distribution were
observed in both CDP7657-treated and saline-treated con-
trol animals. These were considered to be incidental, unre-
lated to CDP7657, and consistent with background levels
observed in historical experiments performed with Rhesus
monkeys. Furthermore, no qualitative morphological dif-
ferences between thrombi were seen between CDP7657-
treated and saline-treated control groups. At the end oftable to CDP7657. Representative hematoxylin and eosin stained
d hu5c8 (a-b), vehicle control (c) or CDP7657 (d). In a and b arterial
intimal layer (arrows). Intimal thickening is mediated by in-migration
and cleft formation. Vessel lumina contain fibrinocellular debris and
thelial lining of thin-walled arterioles (arrows). Under normal conditions,
system. Small pulmonary arterial vessels and capillaries trap thrombi and
These observations were isolated, infrequent findings
Table 4 Thromboembolic potential of CDP7657 in an extended
3-month study in Rhesus monkeys








Controlb 10 (50) 11 581 1.9
(n = 10/sex)
20 mg/kg 6 (60) 9 290 3.1
(n = 5/sex)
50 mg/kg 4 (40) 4 294 1.4
(n = 5/sex)
200 mg/kg 3 (33) 3 261 1.2
(n = 5/sex)
Thromboembolic events defined as the occurrence of a thrombus or an
organizing thrombus (intimal hyperplasia was not observed in this study);
atotal number of lung sections examined in each group = 29/animal; btreated
with i.v. saline
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thrombi were found in the saline-treated control and
CDP7657-treated groups, with a similar low incidence to
those found at the end of the dosing period, indicating no
association with CDP7567 treatment. Thus, even after
prolonged high-dose exposure, there is no evidence that
CDP7657 is able to induce TEs in vivo. In addition, no evi-
dence of other toxicity was demonstrated in this study.
The prothrombotic antibody hu5c8 has a fully func-
tional Fc region and is considered to be capable of anti-
gen cross-linking, whereas CDP7657, an agent that is
not associated with thrombus formation, does not have
an Fc region and is only capable of monovalent binding.
Further investigation of the mechanism by which hu5c8
promotes thrombus formation showed that treatment
with the aglycosyl form of hu5c8 was not associated with
thrombus formation (Table 3).
Discussion
The key role played by the CD40–CD40L axis in regu-
lating T-cell/B-cell interactions makes it a particularly
attractive target for the treatment of inflammatory and
autoimmune diseases. However, the promise of CD40L-
specific antibodies has been challenged by the associ-
ation of hu5c8 with TEs [15, 18]. More recent work has
suggested that these unexpected side effects are likely
dependent upon the anti-CD40L antibody carrying a
functional Fc region [12]. As shown in the pre-clinical
studies presented here, CDP7657, a novel high-affinity
anti-CD40L PEGylated monovalent Fab' antibody frag-
ment that lacks an Fc region, dose-dependently inhibits
the immune response to TT, but does not induce TEs in
monkeys.
In this study, CDP7657 and aglycosyl hu5c8, antibody
constructs that lack a functional Fc region, strongly inhib-
ited the humoral response to TT, although they had re-
duced activity compared with hu5c8 (even allowing forplasma exposure), which almost certainly reflects some
role for an active Fc in this particular model. Interestingly,
aglycosyl hu5c8 has been shown to be effective in the TT
immune response model as well as in SLE and experimen-
tal autoimmune encephalomyelitis mouse models, but was
ineffective in both renal and allograft transplantation
models [23, 25]. This suggests that the contribution of Fc-
effector function of anti-CD40L antibodies may vary de-
pending on the immune challenge [23]. However, in the
current study 60 mg/kg CDP7657 was still able to abro-
gate the immune response to the TT antigen to the same
degree as hu5c8, despite not possessing an Fc.
As has been highlighted previously, anti-CD40L anti-
bodies are particularly effective in mouse SLE models,
showing profound effects on survival as well as pro-
teinuria, autoantibodies and immune cell populations [7].
Interestingly, a more recent study examined disease and
mechanistic endpoints in a CD40L−/− NZB SLE mouse
model [26]. CD40L−/− led to abrogated production of
autoantibodies, decreases in activated T cells and memory
effector cells, lack of germinal center development and re-
duced plasmablast number. These data corroborate data
generated with anti-CD40L antibodies, illustrating that
CD40L has an important role in promoting pathogenic
autoantibody production and kidney disease in NZB mice,
and highlight the potential therapeutic benefit of CD40L
blockade as a treatment for autoimmune diseases, particu-
larly those driven by autoantibodies.
In this study, disease remission was seen with a mur-
ine anti-CD40L PEGylated monovalent Fab' antibody
(MR1 Fab' PEG) in the NZB/W mouse SLE model, using
a therapeutic dosing regimen where mice received anti-
bodies only after they had displayed severe proteinuria.
Most work that has been published using this model uti-
lized a prophylactic dosing regimen, where treatment
was started prior to disease onset. Therapeutic efficacy
has been demonstrated previously with the full-length
MR1 anti-CD40L antibody [24], but the data presented
here suggest that CDP7657, lacking any Fc-function,
may have the potential to be an effective therapy in
lupus patients with demonstrable disease.
Given the previous history of anti-CD40L antibody
evaluation in the clinic, a key requirement for progres-
sing new entities targeting CD40L has been to under-
stand the mechanisms for induction of TE and to design
a suitable in vivo model that could demonstrate that the
risk of TEs associated with anti-CD40L antibodies has
been eliminated. In our studies of isolated human and
Rhesus monkey platelets in vitro, activation occurred
with hu5c8 IC but not with complexes formed with
CDP7657 or other antibody formats lacking an Fc re-
gion. Furthermore, although hu5c8 was shown to acti-
vate human platelets in vitro when it possessed an active
Fc moiety, it was without activity in its aglycosyl form in
Shock et al. Arthritis Research & Therapy  (2015) 17:234 Page 10 of 12these assay systems. Likewise, CDP7657 had no platelet-
activating activity in human or Rhesus monkey platelet
assays.
These observations are consistent with other studies
suggesting a critical role of the IgG Fc regions of anti-
CD40L antibodies in mediating platelet aggregation [20].
In vitro studies showed that hu5c8/CD40L IC, but not
aglycosyl hu5c8 /CD40L IC, activated platelets and that
an anti-FcγRIIa monoclonal antibody can block the acti-
vation of platelets triggered by intact anti-CD40L/
CD40L IC [12, 20]. As FcγRIIa is the only IgG Fc recep-
tor detectably expressed on the surface of platelets [27],
the involvement of other IgG Fc receptors in these ob-
servations is unlikely. More recently, the role of FcγRIIa
in IC-triggered thrombosis was confirmed in transgenic
mice [21] where anti-human CD40L/sCD40L IC trig-
gered a thrombotic response in mice transgenic for hu-
man FcγRIIa, but not in wild-type mice. Furthermore,
the thrombotic effect observed in FcγRIIa transgenic
mice could be triggered by IC comprising soluble mouse
CD40L and the anti-mouse CD40L antibody MR1 carry-
ing a human Fc region (hMR1), but not by IC of soluble
mouse CD40L and aglycosyl hMR1. Overall, the data
suggest a mechanism whereby co-engagement of CD40L
and FcR by an intact antibody triggers activation of
platelets, possibly following cross-linking events and
triggering of signaling; in theory, this could happen in
cis, with co-engagement of CD40L and FcR on the same
platelet surface, or in trans, mediated by platelet–platelet
interactions. In vitro studies published recently with a
domain Ab anti-CD40L antibody, which lacks a func-
tional Fc, similarly concluded that the Fc was essential
for platelet activation [28]. These authors also showed
that an anti-mouse CD40L domain Ab was efficacious in
a number of mouse models of autoimmune disease.
We have previously published work that suggests that
the Rhesus monkey is a relevant and sensitive pre-clinical
model for induction of TEs by anti-CD40L IgG1 antibodies
in humans [19]. In the current study, hu5c8 treatment
produced extensive pulmonary TEs and pulmonary vascu-
lopathy in Rhesus monkeys. In contrast, no treatment-
related adverse findings were observed with CDP7657 or
aglycosyl hu5c8 and the pulmonary findings observed in
CDP7657-treated animals were similar to those observed
in saline-treated control animals. No TEs attributable to
CDP7657 (using doses up to 200 mg/kg i.v.) were observed
in a 3-month repeat dose safety study, either during the
treatment period or after a 6-month treatment-free period,
again in contrast to hu5c8. This is the first demonstration
that a CD40L antibody lacking the Fc domain, and thus no
longer able to activate platelets in vitro, has mitigated the
risk of inducing TEs in vivo in Rhesus monkeys.
In all dose groups, including saline control animals,
33 − 60 % of animals had small, occasional, solitarypulmonary micro-thrombi that were considered to be in-
cidental to injection. It is suspected that these incidental
thrombi may originate from the injection site and/or
blood sampling venipuncture sites, arising secondary to
minor venous trauma [29] and were only observed be-
cause of extensive lung tissue sectioning and high exam-
ination scrutiny.
Published data suggest that the blockade of CD40L
per se would not be expected to cause TE events. Studies
in CD40L−/− knockout mice showed protection against
thrombosis by genetic deficiency in the CD40L pathway
in which accelerated thrombus formation was com-
pletely abrogated in arterioles and partially abrogated in
venules in CD40L−/− mice [30]. Exogenous sCD40L re-
versed this protection. In another study, platelets from
CD40L-deficient mice demonstrated reduced shear-
induced platelet aggregation [31]. Elevated sCD40L has
also been linked to an increased risk of atherothrombo-
sis [32]. It should be stressed that mouse platelets, in
contrast to human and non-human primate platelets, do
not express FcRs and, therefore, these published studies
suggest that blocking CD40L alone would not contribute
to an increased incidence of thrombosis and possibly
would even suppress thrombosis under certain condi-
tions. Indeed, in our studies, the pulmonary thrombo-
vasculopathy observed with hu5c8 in Rhesus monkeys
was dependent on the presence of a functional Fc region,
and was not induced by CD40L blockade alone.
Conclusions
The present studies have demonstrated that anti-CD40L
antibodies require a functional Fc region in order to induce
TEs in Rhesus monkeys. CDP7657, a novel high-affinity
anti-CD40L PEGylated monovalent Fab' antibody without
an Fc region, effectively inhibits CD40L-dependent immune
responses. This, in conjunction with the lack of TE and Fc-
mediated platelet activation, supports the clinical evaluation
of this antibody in humans for the treatment of SLE and
other autoimmune diseases.
Additional files
Additional file 1: Inhibition of secondary immune response in
Cynomolgus monkeys. CDP7657 at 5 or 20 mg/kg (60 mg/kg was not
evaluated in this study) was compared with hu5c8 at 20 mg/kg. Animals
were administered a single dose of antibody or i.v saline. and challenged
with tetanus toxoid (TT) on day 1; they then received a second dose of
antibody and TT on day 30. Data are expressed as the mean anti-TT IgG
titer ± standard deviation; approximately 50 % inhibition was observed at
20 mg/kg CDP7657, although this was not statistically significant. ***P <0.001
(one-way analysis of variance) compared with control; NS not significant.
(PDF 66 kb)
Additional file 2: Hu5c8, aglycosyl hu5c8 and CDP7657 are all
inactive in the absence of sCD40L, as was sCD40L alone. In vitro
platelet aggregation assay of human washed platelets. A Hu5c8 (blue),
CDP7657 (black) and aglycosyl hu5c8 (red) did not cause platelet
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soluble CD40L (rhCD40L). B rhCD40L alone (10 μg/ml) was also inactive.
(PDF 180 kb)
Additional file 3: CDP7657 immune complex (IC) and aglycosyl
hu5c8 IC do not induce platelet aggregation in rhesus monkey
platelets both in the absence of presence of sub-aggregatory
amounts of the platelet agonist (ADP). In vitro aggregation assay of
rhesus monkey washed platelets. A CDP7657 IC did not aggregate rhesus
monkey washed platelets in the absence (blue and red), or presence
(black and green) of ADP. B Similarly, aglycosyl hu5c8 IC did not
aggregate rhesus monkey washed platelets in the absence (blue and red),
or presence (black and green) of ADP. (PDF 171 kb)
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